The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety and efficacy of axitinib in pretreated patients with metastatic renal cell carcinoma: A single center experience of the Medical University of Vienna, Austria.
Ursula Maria Vogl
No relevant relationships to disclose
Lothar Ponhold
No relevant relationships to disclose
Gottfried J Locker
No relevant relationships to disclose
Christoph Zielinski
No relevant relationships to disclose
Christoph Klingler
No relevant relationships to disclose
Gero Kramer
Consultant or Advisory Role - Astellas Pharma; GlaxoSmithKline
Honoraria - Pfizer
Manuela Schmidinger
Consultant or Advisory Role - Astellas Pharma; GlaxoSmithKline; Novartis; Pfizer; Roche
Honoraria - Astellas Pharma; GlaxoSmithKline; Novartis; Pfizer; Roche
Research Funding - GlaxoSmithKline; Pfizer; Roche
Expert Testimony - Pfizer